tert-butoxy-[(S)-2-(5-chloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanol | 871127-39-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: tert-butoxy-[(S)-2-(5-chloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanol
• 英文别名: tert-butyl (2S)-2-(6-chloro-1H-benzimidazol-2-yl)pyrrolidine-1-carboxylate
• CAS: 871127-39-8
• 化学式: C₁₆H₂₀ClN₃O₂
• 分子量: 321.807
• InChiKey: CCNITNQSNBZDOI-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butoxy-[(S)-2-(5-chloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanol 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 6-chloro-2-[(2S)-pyrrolidin-2-yl]-1H-benzimidazole;hydrochloride
  参考文献：
  名称：

  Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity

  摘要：

  Prolycarboxypeptidase (PrCP) is a serine protease that may have a role in metabolism regulation. A class of reversible, potent, and selective PrCP inhibitors was developed starting from a mechanism based design for inhibiting this serine protease. Compound 8o inhibits human and mouse PrCP at IC(50) values of 1 and 2 nM and is not active (IC(50) > 25 mu M) against a panel of closely related proteases. It has lower serum binding than its close analogues and is bioavailable in mouse. Subchronic dosing of 8o in PrCP and WT mice at 100 mg/kg for 5 days resulted in a 5% reduction in body weight in WT mice and a reduction in PrCP KO mice.

  DOI：

  10.1021/jm101013m
• 作为产物：
  描述：

  (S)-N-Boc-吡咯烷-2-甲醛 N-(叔丁氧羰基)-L-脯氨醛 、 4-氯-1,2-苯二胺 以 乙醇 为溶剂， 反应 48.0h， 生成 tert-butoxy-[(S)-2-(5-chloro-1H-benzoimidazol-2-yl)-pyrrolidin-1-yl]-methanol
  参考文献：
  名称：

  DPP-IV inhibitors

  摘要：

  该发明涉及式（I）中的化合物，其中Z、R1-9、n、A、X和Rb的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及其作为药物的生产和使用。

  公开号：

  EP1604989A8

文献信息

• Dpp-IV Inhibitors
  申请人：Edwards John Paul

  公开号：US20080015146A1

  公开（公告）日：2008-01-17

  The invention relates to compounds of formula (I) wherein Z, R 1-9 , n, A, X and R b have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  本发明涉及公式(I)的化合物，其中Z、R1-9、n、A、X和Rb的含义如所述描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。本发明还涉及制备这些化合物的方法，以及作为药物的生产和使用。
• [EN] DPP-IV INHIBITORS<br/>[FR] INHIBITEURS DE LA DPP-IV
  申请人：SANTHERA PHARMACEUTICALS DEUTS

  公开号：WO2005121131A1

  公开（公告）日：2005-12-22

  The invention relates to compounds of formula (I); wherein Z, R1-9, n, A, X and Rb have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.
• Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity
  作者：Changyou Zhou、Margareta Garcia-Calvo、Shirly Pinto、Matthew Lombardo、Zhe Feng、Kate Bender、KellyAnn D. Pryor、Urmi R. Bhatt、Renee M. Chabin、Wayne M. Geissler、Zhu Shen、Xinchun Tong、Zhoupeng Zhang、Kenny K. Wong、Ranabir Sinha Roy、Kevin T. Chapman、Lihu Yang、Yusheng Xiong

  DOI：10.1021/jm101013m

  日期：2010.10.14

  Prolycarboxypeptidase (PrCP) is a serine protease that may have a role in metabolism regulation. A class of reversible, potent, and selective PrCP inhibitors was developed starting from a mechanism based design for inhibiting this serine protease. Compound 8o inhibits human and mouse PrCP at IC(50) values of 1 and 2 nM and is not active (IC(50) > 25 mu M) against a panel of closely related proteases. It has lower serum binding than its close analogues and is bioavailable in mouse. Subchronic dosing of 8o in PrCP and WT mice at 100 mg/kg for 5 days resulted in a 5% reduction in body weight in WT mice and a reduction in PrCP KO mice.
• DPP-IV inhibitors
  申请人：Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft

  公开号：EP1604989A8

  公开（公告）日：2006-03-15

  The invention relates to compounds of formula (I) wherein Z, R1-9, n, A, X and Rb have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式（I）中的化合物，其中Z、R1-9、n、A、X和Rb的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及其作为药物的生产和使用。